Carisma Therapeutics Inc
CARM
View Detailed Chart
0.250USD
-0.033-11.63%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
10.45MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-11.63%
5 Days
-33.15%
1 Month
+5.08%
6 Months
-40.45%
Year to Date
-40.28%
1 Year
-74.50%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
1.000
Target Price
+253.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 19.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 204.15.
Overvalued
The company’s latest PE is -0.21, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.87M shares, decreasing 9.94% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 350.32K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 7.35.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Ticker SymbolCARM
CompanyCarisma Therapeutics Inc
CEOMr. Steven (Steve) Kelly
Websitehttps://sesenbio.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
